Phase III Clinical Trial for OGX_011 – A Treatment for Failed Chemotherapy
At the last ASCO Annual Meeting Saad et al. presented a report about a Phase II trial of custirsen (OGX-011) + docetaxel + prednisone vs. custirsen + mitoxantrone + prednisone in metastatic hormone-refractory prostate cancer. [...]
Why ADT Ultimately Fails
Hair on a man's head offers clues about versatility of a molecule central to Advanced Prostate Cancer. Once again, those of us fighting advanced and recurrent prostate cancer are confronted with contradictory and confusing information. [...]
Caution, Avoid Grapefruit And Other Juices When Taking Certain Drugs
We all know, or at have heard, that drinking grapefruit juice can increase the absorption of certain oral drugs. The result of the increased levels of absorption is the possibility that normal doses of drugs [...]
New York Times – In Cancer Therapy, There Is a Time to Treat and a Time to Let Go
Today’s New York Times had an article written by Jane Brody that discusses the painful issues surrounding the decision to stop treatment, and its negative side effects, and let a cancer survivor live their last [...]
Chemotherapy Is Not So Difficult – A survey
Last April HealthDay News ran an article about chemotherapy and patients fear about starting it. Most cancer survivors involved in a recent survey reported that they had been fearful of undergoing chemotherapy. The good news [...]
Comparing Intermittent To Continuous Androgen Deprivation For Advanced Prostate Cancer
A recent Finnish study released interim results comparing intermittent androgen deprivation (IAD) to continuous androgen deprivation (CAD) in 856 men. All the men had locally advanced or metastatic prostate cancer and they all were treated [...]